Jacob Donoghue, MD, PhD, is the Co-Founder and CEO of Beacon Biosignals, founded in 2019 with the mission of decoding sleep to advance brain health. He leads the company’s efforts to transform how neurological, psychiatric, and sleep disorders are diagnosed and treated using AI-powered sleep EEG analytics.

Under his leadership, Beacon has built a platform that combines FDA-cleared wearable EEG devices with advanced analytics to identify digital neurobiomarkers, supporting precision medicine in clinical trials and diagnostics.

Dr. Donoghue received his MD from Harvard Medical School and PhD in neuroscience from MIT, where his research focused on how neuroactive compounds modulate brain network activity. His scientific work spans neurophysiology, neuropharmacology, and machine learning for neural signal analysis.